600285 Stock Overview
Henan Lingrui Pharmaceutical Co., Ltd. produces and sells medicines in China.
Henan Lingrui Pharmaceutical Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||CN¥11.89|
|52 Week High||CN¥17.97|
|52 Week Low||CN¥9.57|
|1 Month Change||-5.18%|
|3 Month Change||-5.33%|
|1 Year Change||8.19%|
|3 Year Change||46.25%|
|5 Year Change||7.51%|
|Change since IPO||278.85%|
Recent News & Updates
|600285||CN Pharmaceuticals||CN Market|
Return vs Industry: 600285 exceeded the CN Pharmaceuticals industry which returned -16.7% over the past year.
Return vs Market: 600285 exceeded the CN Market which returned -11.4% over the past year.
|600285 Average Weekly Movement||4.4%|
|Pharmaceuticals Industry Average Movement||5.5%|
|Market Average Movement||6.0%|
|10% most volatile stocks in CN Market||9.2%|
|10% least volatile stocks in CN Market||3.9%|
Stable Share Price: 600285 is less volatile than 75% of CN stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: 600285's weekly volatility (4%) has been stable over the past year.
About the Company
Henan Lingrui Pharmaceutical Co., Ltd. produces and sells medicines in China. The company offers its products in ten dosage forms, such as adhesive plasters, tablets, capsules, granules, tinctures, etc. covering approximately 100 product varieties. Its products include Tongluoqutong plasters, Peiyuantongnao capsules, Danlutongdu tablets, stomachache free tablets, Shenqi Hypoglycemic capsules, and others.
Henan Lingrui Pharmaceutical Fundamentals Summary
|600285 fundamental statistics|
Is 600285 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|600285 income statement (TTM)|
|Cost of Revenue||CN¥0|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||0.70|
|Net Profit Margin||14.20%|
How did 600285 perform over the long term?See historical performance and comparison
4.2%Current Dividend Yield
Is 600285 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 5/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 600285?
Other financial metrics that can be useful for relative valuation.
|What is 600285's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does 600285's PE Ratio compare to its peers?
|600285 PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
600851 Shanghai Haixin Group
301263 Guangdong Taienkang Pharmaceutical
300158 Shanxi Zhendong PharmaceuticalLtd
002550 Changzhou Qianhong BiopharmaLTD
600285 Henan Lingrui Pharmaceutical
Price-To-Earnings vs Peers: 600285 is good value based on its Price-To-Earnings Ratio (17x) compared to the peer average (33.2x).
Price to Earnings Ratio vs Industry
How does 600285's PE Ratio compare vs other companies in the CN Pharmaceuticals Industry?
Price-To-Earnings vs Industry: 600285 is good value based on its Price-To-Earnings Ratio (17x) compared to the CN Pharmaceuticals industry average (31x)
Price to Earnings Ratio vs Fair Ratio
What is 600285's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||17x|
|Fair PE Ratio||27x|
Price-To-Earnings vs Fair Ratio: 600285 is good value based on its Price-To-Earnings Ratio (17x) compared to the estimated Fair Price-To-Earnings Ratio (27x).
Share Price vs Fair Value
What is the Fair Price of 600285 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 600285 (CN¥11.89) is trading below our estimate of fair value (CN¥38.17)
Significantly Below Fair Value: 600285 is trading below fair value by more than 20%.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
How is Henan Lingrui Pharmaceutical forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Future Growth Score1/6
Future Growth Score 1/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 600285's forecast earnings growth (17.7% per year) is above the savings rate (3.2%).
Earnings vs Market: 600285's earnings (17.7% per year) are forecast to grow slower than the CN market (24.6% per year).
High Growth Earnings: 600285's earnings are forecast to grow, but not significantly.
Revenue vs Market: 600285's revenue (14.3% per year) is forecast to grow slower than the CN market (17.8% per year).
High Growth Revenue: 600285's revenue (14.3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 600285's Return on Equity is forecast to be low in 3 years time (16.4%).
Discover growth companies
How has Henan Lingrui Pharmaceutical performed over the past 5 years?
Past Performance Score4/6
Past Performance Score 4/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 600285 has high quality earnings.
Growing Profit Margin: 600285's current net profit margins (14.2%) are lower than last year (14.2%).
Past Earnings Growth Analysis
Earnings Trend: 600285's earnings have grown by 10.1% per year over the past 5 years.
Accelerating Growth: 600285's earnings growth over the past year (14.5%) exceeds its 5-year average (10.1% per year).
Earnings vs Industry: 600285 earnings growth over the past year (14.5%) exceeded the Pharmaceuticals industry 6.3%.
Return on Equity
High ROE: 600285's Return on Equity (16.3%) is considered low.
Discover strong past performing companies
How is Henan Lingrui Pharmaceutical's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: 600285's short term assets (CN¥2.2B) exceed its short term liabilities (CN¥1.5B).
Long Term Liabilities: 600285's short term assets (CN¥2.2B) exceed its long term liabilities (CN¥70.8M).
Debt to Equity History and Analysis
Debt Level: 600285 has more cash than its total debt.
Reducing Debt: 600285's debt to equity ratio has reduced from 14.1% to 6.4% over the past 5 years.
Debt Coverage: 600285's debt is well covered by operating cash flow (451.9%).
Interest Coverage: 600285 earns more interest than it pays, so coverage of interest payments is not a concern.
Discover healthy companies
What is Henan Lingrui Pharmaceutical current dividend yield, its reliability and sustainability?
Dividend Score 5/6
Cash Flow Coverage
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: 600285's dividend (4.21%) is higher than the bottom 25% of dividend payers in the CN market (0.46%).
High Dividend: 600285's dividend (4.21%) is in the top 25% of dividend payers in the CN market (1.91%)
Stability and Growth of Payments
Stable Dividend: 600285's dividend payments have been volatile in the past 10 years.
Growing Dividend: 600285's dividend payments have increased over the past 10 years.
Earnings Payout to Shareholders
Earnings Coverage: With its reasonable payout ratio (69.8%), 600285's dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its reasonably low cash payout ratio (44.3%), 600285's dividend payments are well covered by cash flows.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Jianjun Cheng has been General Manager of Henan Lingrui Pharmaceutical Co. Ltd. since June 2011.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Henan Lingrui Pharmaceutical Co., Ltd.'s employee growth, exchange listings and data sources
- Name: Henan Lingrui Pharmaceutical Co., Ltd.
- Ticker: 600285
- Exchange: SHSE
- Founded: 1992
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: CN¥6.639b
- Shares outstanding: 564.55m
- Website: https://www.lingrui.com
Number of Employees
- Henan Lingrui Pharmaceutical Co., Ltd.
- No.666 Jiangjun Road
- Xin County
- Henan Province
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/08/10 00:00|
|End of Day Share Price||2022/08/10 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.